Impact of Ultra-processed Foods in a Population of Patients With Chronic Rheumatic Diseases (Rheumatoid Arthritis, Spondyloarthritis, Osteoarthritis).

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Ultra-processed foods (UPF) represent one of the mainstays of today's diet. They are defined by the NOVA classification system. It was demonstrated that UPF consumption was associated with activity of inflammatory bowel diseases with underlying mechanisms not fully identified yet. It is suspected that UPF constituents could modify the gut microbiota, increase intestinal barrier permeability and directly engage immune surveillance systems, effects that could individually or synergistically increase the risk of immunomediated diseases. As some pathophysiological mechanisms are shared among IBD and rheumatic diseases, we have wondered if UPF consumption could be associated with increased risk of rheumatic disease and/or with their activity. Our primary aim will be to study the pattern of UPF consumption in patients with rheumatic diseases. Our secondary objectives will be to study the activity of diseases according to UPF consumption.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age \> 18 years

• chronic rheumatic disease (Rheumatoid arthritis, spondyloarthritis, osteoarthritis)

• ability to perform questionnaires

Locations
Other Locations
France
Edouard Herriot Hospital
RECRUITING
Lyon
Contact Information
Primary
Maxime AUROUX, MD
Maxime.auroux@chu-lyon.fr
+33472117479
Time Frame
Start Date: 2025-03-31
Estimated Completion Date: 2026-11-30
Participants
Target number of participants: 240
Treatments
Rheumatoid Arthritis
Patients in the first group will correspond to those with rheumatoid arthritis according to ACR criteria of RA
Spondyloarthritis
Patients in the second group will correspond to those with spondyloarthritis according ASDAS criteria
Osteoarthritis
Patients in the third group will correspond to those with spondyloarthritis according ACR criteria
Controls
Patients without rheumatic disease
Sponsors
Leads: Hospices Civils de Lyon

This content was sourced from clinicaltrials.gov

Similar Clinical Trials